This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by LaPlante, K. L.
Right arrow Articles by Mermel, L. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by LaPlante, K. L.
Right arrow Articles by Mermel, L. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2009, p. 3166-3169, Vol. 53, No. 7
0066-4804/09/$08.00+0     doi:10.1128/AAC.01642-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis Strains{triangledown}

Kerry L. LaPlante1,2,4* and Leonard A. Mermel3,4

University of Rhode Island, Department of Pharmacy Practice,1 Infectious Diseases Research Laboratory, Providence Veterans Affairs Medical Center,2 Division of Infectious Diseases, Rhode Island Hospital,3 Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island4

Received 15 December 2008/ Returned for modification 23 February 2009/ Accepted 8 May 2009

We investigated the activities of telavancin and vancomycin against biofilm-producing Staphylococcus and Enterococcus strains. At clinically attainable concentrations, telavancin was active against bacteria embedded in biofilm (minimal biofilm eradication concentration [MBEC], 0.125 to 2 µg/ml) and inhibited biofilm formation at concentrations below the MIC. Vancomycin did not demonstrate the same activity (MBEC, ≥512 µg/ml) against Staphylococcus aureus and Enterococcus faecalis. Telavancin may have a unique role in biofilm-associated infections.

* Corresponding author. Mailing address: University of Rhode Island, Veterans Affairs Medical Center (151), Research Building, 830 Chalkstone Avenue, Providence, RI 02908. Phone: (401) 273-7100, ext. 2339. Fax: (401) 457-3305. E-mail: KerryTedesco{at}uri.edu

{triangledown} Published ahead of print on 18 May 2009.

Antimicrobial Agents and Chemotherapy, July 2009, p. 3166-3169, Vol. 53, No. 7
0066-4804/09/$08.00+0     doi:10.1128/AAC.01642-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»